A woman in Delaware has become the first patient to undergo minimally invasive, endovascular surgery with a polymer-based coil. The coil, manufactured by Embolization, Inc., is a vascular embolization ...

Q3 2025 Earnings Call Transcript November 13, 2025 TriSalus Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.96 EPS, expectations were $-0.17. Operator: Good afternoon, and ...

Discover TriSalus Life Sciences' Q3 2025 earnings: 57% revenue growth, new product launches, and a reaffirmed 50% growth outlook.

IR uses the blood vessel network in the body as almost like a subway map. We can get on and off at different stops to access different parts of the body and treat disease. IR is the intersection of ...

Persistent liver injury halts the regenerative capacity of hepatocytes and activates mechanisms that result in the ...

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT. In an interview with Targeted Oncology at the 2025 North ...

The global interventional oncology market size is expected to reach USD 4.38 billion by 2030, registering a CAGR of 8.55% ...

TriSalus Life Sciences Inc (TLSI) reports a 57% revenue increase, expands its product portfolio, and navigates challenges in manufacturing and reimbursement.

Although the World Thrombosis Day (WTD) officially falls on October 13, this year, it was celebrated in Poland on Saturday, October 11, 2025. The Scientific Conference was held in Warsaw under the ...

While most pregnancies progress normally, there are certain warning signs that, if ignored, could result in serious health ...

According to the NCCN Guidelines for metastatic lung cancer, standard therapies remain valuable, but they are no longer sufficient on their own. This is why molecular profiling, targeted therapy, and ...

The phase III trial studying CRISPR gene editing therapy for transthyretin amyloidosis (ATTR) was paused for safety due to an alarming case of poor liver function in one patient, Intellia Therapeutics ...